Clinical Trial Update: Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of an mRNA-transfected dendritic cell vaccine for androgen-resistant metastatic prostate cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• vaccine therapy with mRNA-transfected dendritic cells

Snippet

Sponsor: Oslo University Hospital | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED